Ousseny Zerbo, PhD

People

Kaiser Permanente Division of Research
2000 Broadway
Oakland, CA 94612

(510) 267-7529 (phone)
ousseny.x.zerbo@kp.org

Ousseny Zerbo, PhD, is a Research Scientist in the Vaccine Study Center at Kaiser Permanente Northern California Division of Research. His research interest is in maternal vaccination during pregnancy and early childhood health outcomes, vaccine uptake, safety and effectiveness. He is the principal investigator on two NIH-funded projects to investigate the effectiveness of influenza vaccination, COVID-19 vaccination during pregnancy, and infant risk of influenza and COVID-19. He also studies risk factors associated with autism spectrum disorders.

Prior to joining the Vaccine Study Center, he completed post-doctoral training in the Autism Research Program at the Division of Research. He received his PhD in epidemiology from the University of California Davis and his bachelor's degree in biological science and teaching credential from the University of Ouagadougou, Burkina Faso, West Africa.

Current Position(s):

Research Scientist II

Section Affiliations:

Infectious Diseases

Primary Research Interests:

Vaccine safety and effectiveness
Autism spectrum disorder

Related Website(s):

Kaiser Permanente Vaccine Study Center

Studies

COVID-19 Vaccine Effectiveness in Pregnant Women and their Infants

The overall goals are to: Determine COVID-19 vaccine effectiveness in pregnant women for preventing laboratory-confirmed COVID-19 and hospitalization for COVID-19 using real-world clinical data; Determine effectiveness of maternal COVID-19 vaccination during pregnancy for infants 0-12 months for outcomes of laboratory-confirmed COVID-19, and hospitalization for COVID-19, and determine whether effectiveness varies by trimester of vaccination; Estimate COVID-19 vaccination rates among pregnant women and identify sociodemographic, geographic clusters and other factors associated with being unvaccinated.
Investigator: Zerbo, Ousseny
Funder: National Institute of Allergy and Infectious Diseases

Analysis to evaluate the effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhea

The goal of this study is to use electronic medical records from 2016 to 2020 to evaluate the protective effect of MenB-4C vaccine against gonococcal infections among 16- to 23-year-old persons.
Investigator: Zerbo, Ousseny
Funder: Centers for Disease Control and Prevention

Effect of Maternal Influenza Vaccination during Pregnancy on Risk of Infant Influenza

This project has three major aims: 1) to examine whether influenza vaccination during pregnancy prevents influenza and other respiratory infections in infants aged 0 to 12 months, with a sub-aim to examine the effect of vaccine timing during pregnancy on these outcomes; 2) to evaluate the effect of maternal influenza vaccination during pregnancy on the effectiveness of influenza vaccine administered to infants; and 3) to examine whether influenza non-vaccination during pregnancy clusters geographically, and determine if those clusters are associated with influenza and influenza-like illnesses during pregnancy.
Investigator: Zerbo, Ousseny
Funder: National Institute of Allergy and Infectious Diseases

Highlighted Publications

Association Between Influenza Infection and Vaccination During Pregnancy and Risk of Autism Spectrum Disorder

Author(s): Zerbo O; Qian Y; Yoshida C; Fireman BH; Klein NP; Croen LA

JAMA Pediatr. 2017 Jan 02;171(1):e163609. Epub 2017-01-02.

Current Position(s):

Section Affiliations:

Primary Research Interests:

Related Website(s):

Studies

COVID-19 Vaccine Effectiveness in Pregnant Women and their Infants

Analysis to evaluate the effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhea

Effect of Maternal Influenza Vaccination during Pregnancy on Risk of Infant Influenza

Highlighted Publications

Association Between Influenza Infection and Vaccination During Pregnancy and Risk of Autism Spectrum Disorder

Publications

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022

Kawasaki Disease Following the 13-valent Pneumococcal Conjugate Vaccine and Rotavirus Vaccines

Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 - VISION Network, August 2021 - March 2022

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022

Maternal SARS-CoV-2 Vaccination and Infant Protection Against SARS-CoV-2 During the First 6 Months of Life

Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study

Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States

Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination

Safety of COVID-19 Vaccination in US Children Ages 5-11 Years

Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022

Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness

Safety of Live-Attenuated Vaccines in Children Exposed to Biologic Response Modifiers in Utero

Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic

Safety of measles and pertussis-containing vaccines in children with autism spectrum disorders

Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022

Population-based assessment of risks for severe COVID-19 disease outcomes

Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021

Contributions of COVID-19 Pandemic-Related Stressors to Racial and Ethnic Disparities in Mental Health During Pregnancy

Associations of COVID-19-Related Health, Healthcare and Economic Factors With Prenatal Depression and Anxiety

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

COVID-19 Vaccination Coverage Among Insured Persons Aged ≥16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021

COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 8, 2021

Genetic associations with a fever after measles-containing vaccines

Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination

COVID-19 prevalence, symptoms, and sociodemographic disparities in infection among insured pregnant women in Northern California

Identification and description of mumps cases in a non-outbreak setting and evaluation of the effectiveness of mumps﻿-containing vaccines over time

Individual and Neighborhood Factors Associated with Failure to Vaccinate against Influenza during Pregnancy

Risk for Subdeltoid Bursitis After Influenza Vaccination: A Population-Based Cohort Study

Parental Risk Factors for Fever in their Children 7-10 Days After the First Dose of Measles-Containing Vaccines

Order of Live and Inactivated Vaccines and Risk of Non-vaccine-targeted Infections in US Children 11-23 Months of Age

Trivalent inactivated influenza vaccine (IIV3) during pregnancy and six-month infant development

Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season

Infection and Fever in Pregnancy and Autism Spectrum Disorders: Findings from the Study to Explore Early Development

An Exploratory Examination of Neonatal Cytokines and Chemokines as Predictors of Autism Risk: The Early Markers for Autism Study

Acellular Pertussis Vaccine Effectiveness Over Time

Factors Affecting Vaccination in Children and Their Siblings After Autism Spectrum Disorder Diagnosis-Reply

Vaccination Patterns in Children After Autism Spectrum Disorder Diagnosis and in Their Younger Siblings

Association Between Estimated Cumulative Vaccine Antigen Exposure Through the First 23 Months of Life and Non-Vaccine-Targeted Infections From 24 Through 47 Months of Age

Use of acellular pertussis vaccines in the United States: can we do better?

No association between influenza vaccination during pregnancy and adverse birth outcomes

Polychlorinated Biphenyl and Organochlorine Pesticide Concentrations in Maternal Mid-Pregnancy Serum Samples: Association with Autism Spectrum Disorder and Intellectual Disability

Autism with intellectual disability is associated with increased levels of maternal cytokines and chemokines during gestation

Association Between Influenza Infection and Vaccination During Pregnancy and Risk of Autism Spectrum Disorder

Kaiser Permanente Northern California pregnancy database: Description and proof of concept study

Maternal mid-pregnancy C-reactive protein and risk of autism spectrum disorders: the early markers for autism study

A Study of Physician Knowledge and Experience with Autism in Adults in a Large Integrated Healthcare System

Maternal Infection During Pregnancy and Autism Spectrum Disorders

The health status of adults on the autism spectrum

Immune mediated conditions in autism spectrum disorders

Neonatal cytokines and chemokines and risk of Autism Spectrum Disorder: the Early Markers for Autism (EMA) study: a case-control study

A genome-wide survey of transgenerational genetic effects in autism

Is maternal influenza or fever during pregnancy associated with autism or developmental delays? Results from the CHARGE (CHildhood Autism Risks from Genetics and Environment) study

​Month of conception and risk of autism

Identification and description of mumps cases in a non-outbreak setting and evaluation of the effectiveness of mumps-containing vaccines over time

Month of conception and risk of autism